Left Atrial Appendage Occlusion for Secondary Stroke Prevention in Patients with Atrial Fibrillation : long-Term Results
| Autor: | Michalina Malec-Litwinowicz, Krzysztof Banaszkiewicz, Radosław Litwinowicz, Krzysztof Bartus, Bogusław Kapelak, Dhanunjaya Lakkireddy, Michał Michalski, Magdalena Bartus |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors medicine.medical_treatment 030204 cardiovascular system & hematology Left atrial appendage occlusion Risk Assessment 03 medical and health sciences Young Adult 0302 clinical medicine Recurrence Risk Factors Internal medicine Atrial Fibrillation Secondary Prevention Medicine Humans Atrial Appendage cardiovascular diseases Thrombus Cardiac Surgical Procedures Stroke Aged Retrospective Studies Aged 80 and over business.industry Vascular disease Mortality rate Anticoagulants Atrial fibrillation Retrospective cohort study Middle Aged medicine.disease Treatment Outcome Neurology Heart failure Cardiology Female Neurology (clinical) Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery |
| Popis: | Background: Patients surviving an initial stroke present a significantly increased risk for further strokes. Left atrial appendage closure (LAAC) became an alternative treatment to pharmacological therapy for stroke prevention in atrial fibrillation (AF) patients. Objective: To evaluate the long-term efficacy of LAAC in primary and secondary stroke prevention in patients with AF. Methods: This retrospective study enrolled 139 patients following LAAC who were divided into 2 groups: 37 patients with prior stroke (Stroke Group) and 102 patients without stroke (Control Group). Overall, cumulative follow-up was 530.1 patient-years. Results: Mean CHADS2, CHA2DS2-VASc scores, and HAS-BLED score were higher in patients with prior stroke compared to patients without stroke (3.0 vs. 1.4, p < 0.0001 and 4.6 vs. 2.3, p < 0.0001, 4.0 vs. 2.8, p < 0.0001, respectively). There were no significant differences between other patient factors (sex, heart failure, hypertension, previous stroke/transient ischemic attack, peripheral vascular disease), which may increase the risk of thromboembolism based on the CHA2DS2-VASc score. Average follow-up was 51.3 months in patients with previous stroke and 50 months in patients without previous stroke. Thromboembolic event rate was 0.8 vs. 0.5 (p = 0.72), bleeding event rate was 0 years vs. 1.4 (p = 0.25), and mortality rates were 0.8 vs. 2.1 (p = 0.38) between the Stroke Group and the Control Group. The estimated reductions in thromboembolic and bleeding risks were 89 and 100%, respectively, in Stroke Group, and 91 and 81%, respectively, in Control Group. Conclusion: Patients with prior stroke may be the preferred group for LAAC regardless of the presence or absence of contraindications for anticoagulant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|